Drug intelligence / Profile preview

FC-1

Development stage
Preclinical
Lead developer
Tsinghua University
Modality
PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
01

Overview

FC-1 is a small molecule proteolysis-targeting chimera (PROTAC) designed to induce the selective degradation of focal adhesion kinase (FAK). Developed by researchers at Tsinghua University, FC-1 consists of a FAK-binding moiety linked to a Cereblon (CRBN) E3 ubiquitin ligase ligand. This bifunctional molecule brings FAK into close proximity with the E3 ligase complex, triggering the polyubiquitination and subsequent proteasomal degradation of the FAK protein. FAK is a non-receptor tyrosine kinase that is frequently overexpressed in various cancers, where it plays a critical role in tumor cell signaling, survival, and metastasis through both its kinase activity and its scaffolding functions. By eliminating the entire protein, FC-1 potentially offers a more comprehensive therapeutic approach than traditional kinase inhibitors, which only block enzymatic activity.

Other names
FAK-degrader 1FAK-degrader1FAK-degrader-1
02

Targets

CRBN (Cereblon)FAK (Focal adhesion kinase)

Beyond the preview

Go deeper on FC-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on FC-1.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call